Rofecoxib: Difference between revisions
Jump to navigation
Jump to search
imported>Joe Quick m (subpages) |
imported>Robert Badgett No edit summary |
||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
'''Rofecoxib''' is a [[cyclooxygenase 2 inhibitors|cyclooxygenase 2 inhibitor]] drug used as an analgesic until it was voluntarily withdrawn from the market by Merck & Co in September, 2004 due to increased cardiovascular complications.<ref>{{cite web |url=http://www.fda.gov/bbs/topics/news/2004/NEW01122.html |title=FDA Issues Public Health Advisory on Vioxx as its Manufacturer Voluntarily Recalls the Product |accessdate=2007-11-18 |format= |work=|year=2004}}</ref> | '''Rofecoxib''' is a [[cyclooxygenase 2 inhibitors|cyclooxygenase 2 inhibitor]] drug used as an analgesic until it was voluntarily withdrawn from the market by Merck & Co in September, 2004 due to increased cardiovascular complications.<ref>{{cite web |url=http://www.fda.gov/bbs/topics/news/2004/NEW01122.html |title=FDA Issues Public Health Advisory on Vioxx as its Manufacturer Voluntarily Recalls the Product |accessdate=2007-11-18 |format= |work=|year=2004}}</ref> This was in part due to concerns<ref name="pmid16339408">{{cite journal |author=Curfman GD, Morrissey S, Drazen JM |title=Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8 |journal=N. Engl. J. Med. |volume=353 |issue=26 |pages=2813–4 |year=2005 |month=December |pmid=16339408 |doi=10.1056/NEJMe058314 |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=16339408&promo=ONFLNS19 |issn=}}</ref> about suppression of negative results due to [[rofecoxib]] in the VIGOR [[randomized controlled trial]]<ref name="pmid11087881">{{cite journal |author=Bombardier C, Laine L, Reicin A, ''et al'' |title=Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group |journal=N. Engl. J. Med. |volume=343 |issue=21 |pages=1520–8, 2 p following 1528 |year=2000 |month=November |pmid=11087881 |doi= |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=11087881&promo=ONFLNS19 |issn=}}</ref>. | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 21:35, 16 April 2009
Rofecoxib is a cyclooxygenase 2 inhibitor drug used as an analgesic until it was voluntarily withdrawn from the market by Merck & Co in September, 2004 due to increased cardiovascular complications.[1] This was in part due to concerns[2] about suppression of negative results due to rofecoxib in the VIGOR randomized controlled trial[3].
References
- ↑ FDA Issues Public Health Advisory on Vioxx as its Manufacturer Voluntarily Recalls the Product (2004). Retrieved on 2007-11-18.
- ↑ Curfman GD, Morrissey S, Drazen JM (December 2005). "Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8". N. Engl. J. Med. 353 (26): 2813–4. DOI:10.1056/NEJMe058314. PMID 16339408. Research Blogging.
- ↑ Bombardier C, Laine L, Reicin A, et al (November 2000). "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group". N. Engl. J. Med. 343 (21): 1520–8, 2 p following 1528. PMID 11087881. [e]